• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Respir Investig . Polymerase-chain reaction testing to prevent hospital-acquired severe acute respiratory syndrome coronavirus 2 infection in Shinju

tetano

Editor, Senior Moderator
Respir Investig


. 2021 Jan 26;S2212-5345(21)00006-X.
doi: 10.1016/j.resinv.2020.12.009. Online ahead of print.
Polymerase-chain reaction testing to prevent hospital-acquired severe acute respiratory syndrome coronavirus 2 infection in Shinjuku, an epicenter in Tokyo: The Tokyo Women's Medical University model


Ken Arimura[SUP] 1 [/SUP], Etsuko Tagaya[SUP] 2 [/SUP], Ken Kikuchi[SUP] 3 [/SUP], Toshihiro Mitsuda[SUP] 4 [/SUP], Gaku Yasuda[SUP] 5 [/SUP], Haruna Azuma[SUP] 6 [/SUP], Naoko Konda[SUP] 7 [/SUP], Yuichi Ikarashi[SUP] 8 [/SUP], Yukihide Chiba[SUP] 9 [/SUP], Kaoru Kusama[SUP] 10 [/SUP], Reiko Sakama[SUP] 5 [/SUP], Shotaro Hagiwara[SUP] 11 [/SUP], Satoru Shimizu[SUP] 12 [/SUP], Ken Shimamoto[SUP] 5 [/SUP], Minoru Nomura[SUP] 13 [/SUP], Arino Yaguchi[SUP] 14 [/SUP], Hiroshi Niinami[SUP] 15 [/SUP], Mitsuko Kondo[SUP] 1 [/SUP], Kazunari Tanabe[SUP] 16 [/SUP], Masatoshi Kawana[SUP] 5 [/SUP]



Affiliations

Abstract

Hospital-acquired severe acute respiratory virus coronavirus 2 (SARS-CoV-2) infection is a healthcare challenge. We hypothesized that polymerase chain reaction testing of symptomatic triaged outpatients and all inpatients before hospitalization in Shinjuku, a coronavirus disease 2019 (COVID-19) epicenter in Tokyo, using the Tokyo Women's Medical University (TMWU) model would be feasible and efficient at preventing COVID-19. This retrospective study enrolled 2981 patients from March to May 2020. The prevalence of SARS-CoV-2 infection was 1.81% (95% credible interval [CI]: 0.95-3.47%) in triaged symptomatic outpatients, 0.04% (95% CI: 0.0002-0.2%) in scheduled asymptomatic inpatients, 3.78% (95% CI: 1.82-7.26%) in emergency inpatients, and 2.4% (95% CI: 1.49-3.82%) in symptomatic patients. There were no cases of hospital-acquired SARS-CoV-2 infection. This shows that the TWMU model could prevent hospital-acquired SARS-CoV-2 infection and is feasible and effective in reducing the impact of SARS-CoV-2 infection in the hospitals.

Keywords: COVID-19; Hospital-acquired infections; PCR testing; SARS-CoV-2; Tokyo Woman's medical university model.
 
Back
Top Bottom